{"disease":{"id":"giant-cell-tumor-of-bone","name":"giant cell tumor of bone"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07227961","title":"PROMIS and Mobility Evaluation in Sarcoma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT00680992","title":"Study of Denosumab in Subjects With Giant Cell Tumor of Bone","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":535,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05402865","title":"A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone","phase":"","overall_status":"COMPLETED","enrollment_count":301,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT03358212","title":"Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03301857","title":"Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06647901","title":"Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Tang Xiaodong","has_results":false},{"nct_id":"NCT00396279","title":"Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04586660","title":"Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT03259152","title":"Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Hebei Medical University Third Hospital","has_results":false},{"nct_id":"NCT03449108","title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04002817","title":"Giant Cell Tumor of the Bone in Young Patients","phase":"","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Istituto Ortopedico Rizzoli","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}